Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. 

South San Francisco, US
Size (employees)
14 (est)+8%
Innoviva is headquartered in South San Francisco, US

Innoviva Office Locations

Innoviva has an office in South San Francisco
South San Francisco, US (HQ)
951 Gateway Blvd

Innoviva Data and Metrics

Innoviva Financial Metrics

Innoviva's revenue was reported to be $133.6 m in FY, 2016 which is a 148% increase from the previous period.

Revenue (FY, 2016)

133.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

59.5 m

EBIT (FY, 2016)

109 m

Market capitalization (23-Jun-2017)

1.4 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

118 m
Innoviva's current market capitalization is $1.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


4.8 m8.4 m53.9 m133.6 m

Revenue growth, %


Operating expense total

173.6 m42.4 m22.4 m24.6 m


(168.9 m)(33.9 m)31.6 m109 m

EBIT margin, %


Interest expense

9.3 m36.9 m51.8 m52.4 m

Interest income

778 k563 k343 k582 k

Pre tax profit

(18.8 m)59.5 m

Net Income

(170.7 m)(168.5 m)(18.8 m)59.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


143.5 m96.8 m159.2 m118 m


10.4 m814 k766 k

Current Assets

483.2 m252.2 m214.3 m198 m


10.2 m324 k221 k368 k

Total Assets

681.3 m521.7 m424.1 m379 m

Accounts Payable

7.6 m818 k128 k

Current Liabilities

84.4 m13.8 m13.5 m20 m

Additional Paid-in Capital

1.8 b1.5 b1.4 b1.3 b

Retained Earnings

(1.5 b)(1.7 b)(1.7 b)(1.6 b)

Total Equity

299.1 m(223.3 m)(342.6 m)(353 m)

Financial Leverage

2.3 x-2.3 x-1.2 x-1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(170.7 m)(168.5 m)(18.8 m)59.5 m

Depreciation and Amortization

8.2 m12.2 m13.9 m14 m


(3.1 m)(1.9 m)

Accounts Payable

1.6 m(7.7 m)818 k(690 k)

Cash From Operating Activities

(129.6 m)(130.7 m)10.1 m61 m

Purchases of PP&E

(2.7 m)(689 k)(7 k)(278 k)

Cash From Investing Activities

(219.6 m)(65.1 m)159.2 m(4.6 m)

Cash From Financing Activities

397.8 m149.1 m(106.9 m)(97.6 m)

Interest Paid

8 m9.2 m25.9 m48.8 m
USDY, 2016


10.3 m

Financial Leverage

-1.1 x

Innoviva Operating Metrics

FY, 2016

Patents Issued


Patents Granted


Innoviva Market Value History

Innoviva News and Updates

Innoviva Company Life and Culture

You may also be interested in